Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

(14) Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (infertility and permanent birth control).

The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

 Significant segment expenses, as provided to the CODM are as follows:

	2024			2023
Sales	$	1,629,108			1,071,970
Cost of sales (excluding depreciation expense)		544,903			380,069
Research and development expense		2,217,610			2,051,902
Other research and development expenses1		5,998,933			5,156,799
Total research and development expense		8,216,543			7,208,701
Sales and marketing expense		4,030,150			650,126
General and administrative expense		6,325,999			6,858,008
Depreciation and amortization expense		297,318			483,481
Total Operating expenses		18,870,010			15,200,316
Total other (expense) income		(1,021,221	)		265,629
Loss before income taxes		(18,807,026	)		(14,242,786	)
Income tax expense		9,602			4,338
Net loss	$	(18,816,628	)		(14,247,124	)

¹ Other research and development expenses include clinical affairs, regulatory, manufacturing and quality assurance expenses.